Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

37 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
CDKN2A as a uveal and cutaneous melanoma susceptibility gene.
Kannengiesser C, Avril MF, Spatz A, Laud K, Lenoir GM, Bressac-de-Paillerets B. Kannengiesser C, et al. Among authors: laud k. Genes Chromosomes Cancer. 2003 Nov;38(3):265-8. doi: 10.1002/gcc.10286. Genes Chromosomes Cancer. 2003. PMID: 14506702
Comprehensive analysis of CDKN2A (p16INK4A/p14ARF) and CDKN2B genes in 53 melanoma index cases considered to be at heightened risk of melanoma.
Laud K, Marian C, Avril MF, Barrois M, Chompret A, Goldstein AM, Tucker MA, Clark PA, Peters G, Chaudru V, Demenais F, Spatz A, Smith MW, Lenoir GM, Bressac-de Paillerets B; French Hereditary Melanoma Study Group. Laud K, et al. J Med Genet. 2006 Jan;43(1):39-47. doi: 10.1136/jmg.2005.033498. Epub 2005 Jun 3. J Med Genet. 2006. PMID: 15937071 Free PMC article.
Cutaneous phenotype and MC1R variants as modifying factors for the development of melanoma in CDKN2A G101W mutation carriers from 4 countries.
Goldstein AM, Chaudru V, Ghiorzo P, Badenas C, Malvehy J, Pastorino L, Laud K, Hulley B, Avril MF, Puig-Butille JA, Miniere A, Marti R, Chompret A, Cuellar F, Kolm I, Mila M, Tucker MA, Demenais F, Bianchi-Scarra G, Puig S, de-Paillerets BB. Goldstein AM, et al. Among authors: laud k. Int J Cancer. 2007 Aug 15;121(4):825-31. doi: 10.1002/ijc.22712. Int J Cancer. 2007. PMID: 17397031 Free article.
BRAF as a melanoma susceptibility candidate gene?
Laud K, Kannengiesser C, Avril MF, Chompret A, Stoppa-Lyonnet D, Desjardins L, Eychene A, Demenais F, Lenoir GM, Bressac-de Paillerets B; French Herediatary Melanoma Study Group. Laud K, et al. Cancer Res. 2003 Jun 15;63(12):3061-5. Cancer Res. 2003. PMID: 12810628
Common variants near TARDBP and EGR2 are associated with susceptibility to Ewing sarcoma.
Postel-Vinay S, Véron AS, Tirode F, Pierron G, Reynaud S, Kovar H, Oberlin O, Lapouble E, Ballet S, Lucchesi C, Kontny U, González-Neira A, Picci P, Alonso J, Patino-Garcia A, de Paillerets BB, Laud K, Dina C, Froguel P, Clavel-Chapelon F, Doz F, Michon J, Chanock SJ, Thomas G, Cox DG, Delattre O. Postel-Vinay S, et al. Among authors: laud k. Nat Genet. 2012 Feb 12;44(3):323-7. doi: 10.1038/ng.1085. Nat Genet. 2012. PMID: 22327514
Oncostatin M is a growth factor for Ewing sarcoma.
David E, Tirode F, Baud'huin M, Guihard P, Laud K, Delattre O, Heymann MF, Heymann D, Redini F, Blanchard F. David E, et al. Among authors: laud k. Am J Pathol. 2012 Nov;181(5):1782-95. doi: 10.1016/j.ajpath.2012.07.023. Epub 2012 Sep 13. Am J Pathol. 2012. PMID: 22982441
37 results